Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Full text not available from this repository.| Item Type: | Article |
|---|---|
| Status: | Published |
| Official URL: | https://doi.org/10.1016/j.ejpb.2019.08.004 |
| Journal or Publication Title: | European Journal of Pharmaceutics and Biopharmaceutics |
| Volume: | 142 |
| Page Range: | pp. 543-552 |
| Date: | 2019 |
| Divisions: | Tuberculosis |
| Depositing User: | General Admin |
| Identification Number: | 10.1016/j.ejpb.2019.08.004 |
| ISSN: | 09396411 |
| Date Deposited: | 21 Dec 2020 23:17 |
| Abstract: | Recently we showed that nebulized ciprofloxacin and phage PEV20 in combination had a synergistic bactericidal effect against antibiotic-resistant Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Compared to nebulization, dry powders for inhalation may improve patient handling characteristics and compliance. In the present study, we co-spray dried ciprofloxacin and phage PEV20 using L-leucine with or without lactose as excipients. Two formulations were identified for testing in this study. The mass ratios were set at 1:1:1 for ciprofloxacin, lactose and L-leucine (Formulation A) or 2:1 for ciprofloxacin and L-leucine without lactose (Formulation B). Concentrations of PEV20 were set at 108 and 109 PFU/mL for two clinical P. aeruginosa strains FADD1-PA001 and JIP865, respectively. Formulations A and B were characterized as partially crystalline and the powders recrystallized at >40% relative humidity (RH). Both formulations exhibited strong synergistic antimicrobial killing effect on the two strains. Formulations A and B maintained bactericidal synergy after dispersion using both low and high resistance Osmohaler™. Powder aerosol performance was examined by next generation impactor (NGI) in low resistance inhaler at 100 L/min and by multi-stage liquid impinger (MSLI) in high resistance inhaler at 60 L/min. Fine particle fractions (FPF) obtained by NGI were 59.7 ± 2.1% and 64.3 ± 2.9% for A and B, respectively. FPF obtained by MSLI were 71.0 ± 3.4% and 73.3 ± 5.0%, respectively. In conclusion, it is feasible to prepare stable and inhalable combination powder formulations of phage PEV20 and ciprofloxacin for potential treatment of respiratory infections caused by multi-drug resistant (MDR) P. aeruginosa. Keywords: Bacteriophages; Ciprofloxacin; Cystic fibrosis; Inhalation; L-leucine; Powder formulation; Pseudomonas aeruginosa; Respiratory infection; Spray drying. Copyright © 2019 Elsevier B.V. All rights reserved. |
| Creators: | Creators Email Lin, Yu UNSPECIFIED Chang, Rachel Yoon Kyung UNSPECIFIED Britton, Warwick J. UNSPECIFIED Morales, Sandra UNSPECIFIED Kutter, Elizabeth UNSPECIFIED Li, Jian UNSPECIFIED Chan, Hak-Kim UNSPECIFIED |
| Last Modified: | 21 Dec 2020 23:17 |
| URI: | https://eprints.centenary.org.au/id/eprint/149 |
Actions (login required)
 |
View Item |
